Extended Data Table 2 Investigator-Assessed Best Overall Response per RECIST v1.1 at Ad Hoc Analysis (ITT Population With Measurable Disease at Baseline)

From: Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial